Primary XXXX : experience with @entity3733 therapy.

@entity1 @entity1494 @entity2783 @entity3885 @entity3733 @entity811
PURPOSE: We present our long-term experience with intravesical @entity3733 ( @entity3733 ) for primary @entity1494 . MATERIALS AND METHODS: The study included 4 males and 2 females 28 to 68 years old (mean age 54) at diagnosis of biopsy proven primary @entity2783 involving the bladder diffusely or extensively in 1 locale. All @entity1 had normal upper urinary tracts. They continued to be symptomatic ( @entity811 in 3, irritative voiding symptoms in 1, and @entity811 and irritative voiding symptoms in 2) despite conventional transurethral destructive therapy. Every 2 weeks they received 30-minute instillations of 50 ml. 50% @entity3733 intravesically for 3 months ( @entity1 1), 6 months (1) and 1 year (4). RESULTS: Therapy failed at 3 and 6 months in 2 @entity1 of whom 1 with a contracted bladder underwent cystectomy and another was stabilized for 1 year with laser therapy. In the remaining 4 @entity1 who were followed for 6 years disease stabilized for 2 to 6 years (mean 3.5) but 3 later required additional therapy including repeat @entity3733 in 1 and laser therapy in 2. CONCLUSIONS: Diffuse or locally extensive @entity1494 by primary @entity2783 usually fails to respond to conventional transurethral destructive surgical procedures. Collectively, our experience and the literature suggest that intravesical @entity3733 can be a bladder saving measure and help resolve @entity3885 in some @entity1 . High recurrence rate mandates lifelong cystoscopic surveillance.
